Dravet Syndrome, Tuberous sclerosis complex, Lennox-Gastaut Syndrome research hub

An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in Participants with Tuberous Sclerosis Complex (1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately‑controlled Seizures

This study looks at a medicine called Epidyolex for young children with Dravet Syndrome, Tuberous Sclerosis Complex, or Lennox-Gastaut Syndrome. It checks if the medicine is safe, how much stays in the body, and if it helps reduce seizures. This is a big final-stage study.